0.05
+0(+0.00%)
Currency In USD
| Previous Close | 0.05 |
| Open | 0.05 |
| Day High | 0.05 |
| Day Low | 0.05 |
| 52-Week High | 2.1 |
| 52-Week Low | 0.03 |
| Volume | 1,043 |
| Average Volume | 22,062 |
| Market Cap | 189,249 |
| PE | -0.01 |
| EPS | -4.01 |
| Moving Average 50 Days | 0.04 |
| Moving Average 200 Days | 0.68 |
| Change | 0 |
If you invested $1000 in IMAC Holdings, Inc. (BACK) since IPO date, it would be worth $0.45 as of July 02, 2025 at a share price of $0.05. Whereas If you bought $1000 worth of IMAC Holdings, Inc. (BACK) shares 5 years ago, it would be worth $1.37 as of July 02, 2025 at a share price of $0.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
GlobeNewswire Inc.
Feb 24, 2025 1:15 PM GMT
Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response t
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
GlobeNewswire Inc.
Feb 19, 2025 2:15 PM GMT
Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink Tec
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
GlobeNewswire Inc.
Feb 10, 2025 2:15 PM GMT
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), announces the publ